CTOs on the Move

Targacept

www.targacept.com

 
Targacept`s clinical pipeline is built on a unique class of therapeutic targets.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.targacept.com
  • 100 N Main St Ste 1510
    Winston Salem, NC USA 27101
  • Phone: 336.480.2100

Executives

Name Title Contact Details

Similar Companies

Biolex Therapeutics

Biolex Therapeutics is a Pittsboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ValenzaBio

ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.

Provista Life Sciences

Provista Life Sciences is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xpogen

Xpogen is a Newton Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ARCA biopharma

ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.